Aortech Share Discussion Threads

[langland] 25/10/2019 09:10

That's a good trade by someone. Bought yesterday at 75- sold today at 73.5.

[bones] 24/10/2019 16:14

Also difficult to buy any GR. Quoting online for 2500 max at full ask 77

[greedy rooster] 24/10/2019 15:11

They're bidding 73.5p for 5000, i think this has momentum to test the 2018 high and with an update forecast for late November, that could underpin the break-out that beckons from the long-term chart as Stig mentioned earlier. And yet few know about it...happy days.

[the stigologist] 24/10/2019 14:43

I think we could move up quite quickly now given the double/triple whammy of

- Overhang lifted (Miton)
- Industry acceptance/awareness of technology (Biomerics etc)
- Comparitor valuations (Foldax / Goldman Sachs rumours)

That is before any news from the Company itself.

[someuwin] 24/10/2019 14:39

Now we know Miton are out and no longer putting constant downward pressure on the price, hopefully we'll see the price gravitating more towards Stockdale's 400p initial target.

[ny boy] 23/10/2019 19:09

90p initial price target

[the stigologist] 23/10/2019 19:07

Long term chart looking quite tasty as well.

[bones] 23/10/2019 16:43

New 6 month high at close. Interesting to see a bidder in the closing auction at 72p for 20,000 shares. Nobody sold to bidder. Stock is hard to come by now that Miton have sold out their position (due to their specific redemption problems).

[someuwin] 23/10/2019 12:41

...And thus another small buy ticks it up.

[someuwin] 23/10/2019 11:50

That £10k buy has taken most of the free stock.

Can now buy £3k online. But not £4k.

[bones] 21/10/2019 20:15

Thankfully, the AOR board is not the type to attempt to hype the share price with fatuous RNS releases. It may well be that the industry chatter we are hearing of will do the bidding for us in the meantime! The Biomerics tweet is a case in point as well as the information exchanged among the industry leaders at the recent Lisbon event.

Personally speaking, I would like to see the market re-rate the share price so that it reflects the promise and then we can have an update later when something of substance arises.

[coolhandfluke] 21/10/2019 17:56

Was it only 10 days ago? Feels a lot longer. Still, I reckon they will be champing at the bit to get all the good news out now that things appear to be moving forward promisingly.

[bones] 21/10/2019 15:29

End of November is the expectation for the interims, CHF. We’ve only had a trading update 10 days ago!

“ A further update will be provided at the time of the release of the Company's unaudited interim results for the six months ended 30 September 2019, which is expected to be in late November 2019.”

[coolhandfluke] 21/10/2019 15:22

Building ahead of the next update due in couple of weeks or so.

[donalc] 21/10/2019 15:10

on tiny volumes.

[davisc5] 21/10/2019 14:50

Looking good, triple bottom.

[landy90] 19/10/2019 08:15

I find the Biomerics Tweet very interesting. Biomerics is a sub contract manufacturer for all the big device companies. They are very customer focussed. My guess is their customers have been asking them about Aortech. The industry has been a bit dismissive of polymer valves in the past but is now taking real notice of the recent first in man. Polymer valves and Elasteon are being talked about!!

[bones] 18/10/2019 17:53

Yes, as you say, AorTech outsourced manufacturing of the polymer under licence to Biomerics (since 2013, I think). AorTech earns ongoing royalties and fees from sales etc made by Biomerics of devices which incorporate Elasteon and Ecsil.

The polymers for RUA Medical will be under separate contracts, as those are direct purchases by RUA, I understand (happy to be corrected on that).

I think it’s good that Biomerics have seen fit to publicise and even praise their partner, AorTech!

[nextlink] 18/10/2019 16:51

I take it that Aortech have licensed Biomerics for many years
to manufacture the Polymer.
That RUA Medical are to small to take on that role and are developing
the mesh to which the polymer is then added.
As you state when I read your reply properly.

[bones] 18/10/2019 16:41

I don't believe that is right Nextlink. Biomerics will still be the supplier of the polymer to RUA Medical who have been contracted by Aortech to manufacture the patches and grafts for Aortech. This is no threat to Biomerics who remain an important link in Aortech's strategy. That is my firm understanding.

Biomerics manufacture the polymer, RUA will manufacture the devices using the polymer acquired from Biomerics.

[nextlink] 18/10/2019 16:35

Aerotech have been working closely with RUA Medical to
manufacture and cut out the middleman ie Biomerics.
RUA Medical have supported Aerotech to keep costs down and
no doubt would benefit more than would normally be the case
for a manufacturer. - At a future date.
I wonder if Biomerics have suddenly realized what has been
going on for over a year in the UK.
If so I would imagine a lot of US Companies in this sector will
be mulling over their options.

I suppose the market is so large there is no reason why Biomerics
should not manufacture the new products alongside RUA Medical, perhaps
under licence to RUA Medical.

[bones] 18/10/2019 16:11

It's out of character donalc!, I have always looked in vain for anything "Aortech" or "Elast-eon" from them in the past, publicity-wise. They brand their product Quadrasil



but, in the tweet, refer specifically to Elast-eon and EcSil which are the Aortech branding names. Whatever the reason, it is all good publicity and hopefully drums up business longer term! After all, Biomerics has plenty of firepower for advertising and marketing and they should be pushing the benefits of these more pricey devices that use top quality materials like Elast-eon, IMO!

[donalc] 18/10/2019 15:57

Maybe it is just what it says- they like the update and proud to be a partner!?
But someone has bought a little bit as a result of it.

[bones] 18/10/2019 15:04

That’s a solid tweet there from Biomerics, Stig. Wonder what brought that on from them!